Bekadja Mohamed Amine, Niederwiser Dietger, Kharfan-Dabaja Mohamed A, El Fakih Riad, Garderet Laurent, Yakoub-Agha Ibrahim, Greinix Hildegard, Weisdorf Daniel J, Galeano Sebastian, Ahmed Syed Osman, Chabanon Christian, Hashmi Shahrukh K, Ruggeri Annalisa, Gergis Usama, Bazarbachi Ali, Hamad Nada, Albeihany Amal, Pasquini Marcelo, Hanbali Amr, Szer Jeff, Kodera Yoshihisa, Kumar Ambuj, Elhassan Tusneem, McLornan Donal, Worel Nina, Greco Raffaella, Mohty Mohamad, Atsuta Yoshiko, Koh Mickey, Sureda Anna, Rondelli Damiano, Aljurf Mahmoud, Rasheed Walid
EHU 1st November, Oran, Algeria.
Division of Hematology and Medical Oncology, University of Leipzig, Leipzig, Germany.
Bone Marrow Transplant. 2025 Jan;60(1):19-27. doi: 10.1038/s41409-024-02431-y. Epub 2024 Oct 7.
Autologous peripheral blood stem cell (PBSC) transplantation is a standard treatment of multiple myeloma (MM), Hodgkin lymphoma and various subtypes of non-Hodgkin lymphoma. Cryopreservation of hematopoietic stem cells is standard practice that allows time for delivery of conditioning regimen prior to cell infusion. The aim of this Worldwide Network for Blood & Marrow Transplantation (WBMT) work was to assess existing evidence on non-cryopreserved autologous transplants through a systematic review/meta-analysis, to study feasibility and safety of this approach. We searched PubMed, Web of Science and SCOPUS for studies that utilized non-cryopreserved autologous PBSC transplantation. Identified literature was reviewed for information on mobilization, apheresis, preservation and viability, conditioning regimen, engraftment, response, and survival. Results highlight collective experience from 19 transplant centers (1686 patients), that performed autologous transplants using non-cryopreserved PBSCs. The mean of infused CD34+ was 5.6 × 10/kg. Stem cell viability at transplantation was >90% in MM and >75% in lymphomas, after a storage time of 24-144 h at +4 °C. Mean time-to-neutrophil engraftment was 12 days and 15.3 days for platelets. Pooled proportion estimates of day 100 transplant-related mortality and graft failure were 1% and 0%, respectively. Non-cryopreservation of apheresed autologous PBSCs appears feasible and safe.
自体外周血干细胞（PBSC）移植是多发性骨髓瘤（MM）、霍奇金淋巴瘤和各种非霍奇金淋巴瘤亚型的标准治疗方法。造血干细胞的冷冻保存是标准做法，它允许在细胞输注前有时间进行预处理方案。全球血液与骨髓移植网络（WBMT）这项工作的目的是通过系统评价/荟萃分析评估非冷冻保存自体移植的现有证据，以研究这种方法的可行性和安全性。我们在PubMed、科学网和Scopus中搜索了使用非冷冻保存自体PBSC移植的研究。对已识别的文献进行了审查，以获取有关动员、单采、保存和活力、预处理方案、植入、反应和生存的信息。结果突出了19个移植中心（1686例患者）的集体经验，这些中心使用非冷冻保存的PBSC进行了自体移植。输注的CD34+的平均值为5.6×10/kg。在4℃下储存24 - 144小时后，MM患者移植时干细胞活力>90%，淋巴瘤患者>75%。中性粒细胞植入的平均时间为12天，血小板为15.3天。移植后第100天与移植相关的死亡率和移植物失败的合并比例估计分别为1%和0%。单采的自体PBSC非冷冻保存似乎是可行和安全的。
